Fusen Pharmaceutical Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Fusen Pharmaceutical.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	11.1%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

May 21

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Mar 31

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Feb 08

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Jan 18

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Dec 28

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition

Dec 07

If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns

Nov 20

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Fusen Pharmaceutical non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

SEHK:1652 - Stime future degli analisti e dati finanziari passati (CNY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	425	-90	-127	-33	N/A
3/31/2024	496	-63	-144	-53	N/A
12/31/2023	566	-36	-162	-73	N/A
9/30/2023	614	-24	-49	19	N/A
6/30/2023	663	-11	64	110	N/A
3/31/2023	577	-23	75	110	N/A
12/31/2022	492	-35	87	110	N/A
9/30/2022	414	-34	-5	38	N/A
6/30/2022	337	-34	-96	-34	N/A
3/31/2022	361	-9	-79	7	N/A
12/31/2021	386	17	-62	48	N/A
9/30/2021	420	48	-30	66	N/A
6/30/2021	454	79	3	83	N/A
3/31/2021	470	75	49	118	N/A
12/31/2020	487	70	95	153	N/A
9/30/2020	473	67	74	154	N/A
6/30/2020	458	65	53	154	N/A
3/31/2020	433	59	8	87	N/A
12/31/2019	407	53	-37	20	N/A
9/30/2019	397	63	-54	23	N/A
6/30/2019	387	72	-71	26	N/A
3/31/2019	424	87	-56	44	N/A
12/31/2018	462	102	-42	63	N/A
9/30/2018	507	102	37	95	N/A
6/30/2018	493	98	68	82	N/A
3/31/2018	473	98	N/A	107	N/A
12/31/2017	453	97	N/A	133	N/A
9/30/2017	427	86	N/A	91	N/A
12/31/2016	442	95	N/A	172	N/A
12/31/2015	369	45	N/A	70	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if 1652's forecast earnings growth is above the savings rate (2.3%).

Guadagni vs Mercato: Insufficient data to determine if 1652's earnings are forecast to grow faster than the Hong Kong market

Guadagni ad alta crescita: Insufficient data to determine if 1652's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if 1652's revenue is forecast to grow faster than the Hong Kong market.

Ricavi ad alta crescita: Insufficient data to determine if 1652's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if 1652's Return on Equity is forecast to be high in 3 years time

Fusen Pharmaceutical Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Recent updates

Eltrombopag Olamine Tablets Developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Obtains the Approval for Marketing from the National Medical Products Administration of China

Fusen Pharmaceutical Company Limited Announces Acceptance of Application for Consistency Evaluation of Nicardipine Hydrochloride Injection

First half 2024 earnings released: CN¥0.05 loss per share (vs CN¥0.022 profit in 1H 2023)

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2024

Fusen Pharmaceutical Company Limited to Report First Half, 2024 Results on Aug 29, 2024

Fusen Pharmaceutical Company's Subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces Acceptance of Clinical Trial Application for ``SY617''

New minor risk - Market cap size

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Fusen Pharmaceutical Company Limited, Annual General Meeting, May 28, 2024

CEO & Executive Director recently bought HK$224k worth of stock

Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited Announces National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Metformin Empagliflozin Tablets (I)

Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.046 loss in FY 2022)

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.022 (vs CN¥0.009 loss in 1H 2022)

Fusen Pharmaceutical Company Limited to Report Q2, 2023 Results on Aug 29, 2023

Fusen Pharmaceutical Company Limited Provides Group Earnings Guidance for the Six Months Ended 30 June 2023

Executive Chairman recently bought HK$84k worth of stock

CEO & Executive Director recently bought HK$1.0m worth of stock

Full year 2022 earnings released: CN¥0.046 loss per share (vs CN¥0.022 profit in FY 2021)

Executive Chairman recently bought HK$1.1m worth of stock

Executive Chairman recently bought HK$918k worth of stock

CEO & Executive Director recently bought HK$375k worth of stock

Executive Chairman recently bought HK$791k worth of stock

Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky

Executive Chairman recently bought HK$2.3m worth of stock

Less than half of directors are independent

CEO & Executive Director recently bought HK$2.2m worth of stock

Executive Chairman recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$2.0m worth of stock

CEO & Executive Director recently bought HK$658k worth of stock

CEO & Executive Director recently bought HK$79k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

First half 2022 earnings released: CN¥0.01 loss per share (vs CN¥0.057 profit in 1H 2021)

Fusen Pharmaceutical Company Limited Does Not Recommend Dividend for the Six Months Ended June 30, 2022

Fusen Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Fusen Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 29, 2022

CEO & Executive Director recently bought HK$157k worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

CEO & Executive Director recently bought HK$1.9m worth of stock

Fusen Pharmaceutical Company Limited Declares Final Dividend for the Year Ended 31 December 2021

Less than half of directors are independent

Investor sentiment improved over the past week

CEO & Executive Director recently bought HK$856k worth of stock

CEO & Executive Director recently bought HK$2.1m worth of stock

Investor sentiment deteriorated over the past week

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS CN¥0.057 (vs CN¥0.044 in 1H 2020)

Investor sentiment deteriorated over the past week

Fusen Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2020

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.089 (vs CN¥0.067 in FY 2019)

Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS CN¥0.09 (vs CN¥0.067 in FY 2019)

Investor sentiment improved over the past week

Fusen Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns

New 90-day low: HK$4.17

We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide

Company Secretary has left the company

Fusen Pharmaceutical Company Limited Announces Executive Changes, with Effect from 29 January 2021

Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?

Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition